SCHEMBL18650751

SCHEMBL18650751

O=C(O)c1ccc2ccccc2c1Nc1cccc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.56
WDR5 P61964 1/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
NR4A1 P22736 1/20 0.53
NR4A2 P43354 1/20 0.53
NR4A3 Q92570 1/20 0.53
LDHA P00338 1/20 0.53
CDC25B P30305 6/20 0.51
CYP3A4 P08684 2/20 0.51
HPGD P15428 2/20 0.51
ALDH1A1 P00352 2/20 0.51
TP53 P04637 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
ATM Q13315 1/20 0.51
GRIK1 P39086 1/20 0.51
NPC1 O15118 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1147050 0.81 CDC25B (0.71) HSD17B10MEN1KMT2ANR4A1NR4A2
SCHEMBL30519263 0.81 CDC25B (0.71) HSD17B10MEN1KMT2ANR4A1NR4A2
SCHEMBL16737157 0.79 MEN1 (0.69) HSD17B10MEN1KMT2ANR4A1NR4A2
SCHEMBL4593816 0.78 CDC25B (0.61) WDR5MEN1KMT2ANR4A1NR4A2
SCHEMBL31531051 0.78 WDR5 (0.59) HSD17B10WDR5MEN1KMT2ANR4A1
SCHEMBL11795612 0.77 CDC25B (0.52) WDR5MEN1KMT2ANR4A1NR4A2
SCHEMBL11799867 0.77 CLCN2 (0.63) MEN1KMT2ANR4A1NR4A2CDC25B
SCHEMBL11799846 0.77 FTO (0.58) MEN1KMT2ANR4A1NR4A2NR4A3
SCHEMBL29061899 0.76 HSD17B10 (0.53) HSD17B10MEN1KMT2ACDC25BCYP3A4
SCHEMBL11690219 0.76 GRIK1 (0.76) HSD17B10MEN1KMT2ACDC25BGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10377784-B2 Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith WAKE FOREST UNIVERSITY (US) 2019-08-13 US disclosed
US-10023599-B2 Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith WAKE FOREST UNIVERSITY (US) 2018-07-17 US disclosed
US-10023599-B2 Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith WAKE FOREST UNIVERSITY (US) 2018-07-17 US disclosed
US-20170081351-A1 Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith WAKE FOREST UNIVERSITY 2017-03-23 US disclosed
US-20170081351-A1 Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith WAKE FOREST UNIVERSITY 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023599-B2 Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith ACR, TP53, MCL1 HSD17B10 1554/4885WDR5 2406/4885MEN1 1372/4885
US-10377784-B2 Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith ACR, TP53, BAD HSD17B10 1374/4885WDR5 2259/4885MEN1 1481/4885
US-20170081351-A1 Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith ACR, TP53, MCL1 HSD17B10 1554/4885WDR5 2406/4885MEN1 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.